Inhalative Analgosedierung auf der Intensivstation: Gefahr einer malignen Hyperthermie

W. Klingler; E. Pfenninger

doi:10.1007/s00063-018-0453-7

Inhalative Analgosedierung auf der Intensivstation: Gefahr einer malignen Hyperthermie

Translated title of the contribution: Inhalational analgosedation in the intensive care unit: Risk of malignant hyperthermia

W. Klingler
, E. Pfenninger

Kliniken Landkreis Sigmaringen GmbH
University Medical Center Ulm and Center of Excellence 'Metabolic Disorders'

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Background: According to the 2010 S3 Guidelines, analgosedation is an option for ventilated patients in intensive care units (ICU). Therefore, adverse effects of volatile anesthetics can occur in areas outside of surgical medical fields. Objective: The aim is to inform ICU physicians about the clinical and legal challenges of a life-threatening pharmacogenetic reaction to inhalational anesthetics, malignant hyperthermia (MH). Discussion: Consequences of an MH crisis for doctors, patients, and relatives regarding patient rights legislation, as well as insurance and employment issues with respect to the German Genetic Diagnostics Act are discussed.

Translated title of the contribution	Inhalational analgosedation in the intensive care unit: Risk of malignant hyperthermia
Original language	German
Pages (from-to)	101-106
Number of pages	6
Journal	Medizinische Klinik - Intensivmedizin und Notfallmedizin
Volume	115
Issue number	2
DOIs	https://doi.org/10.1007/s00063-018-0453-7
State	Published - 1 Mar 2020
Externally published	Yes

Access to Document

10.1007/s00063-018-0453-7

Cite this

@article{bd2c21e4b8844e4baa51ad3cc93cc61d,

title = "Inhalative Analgosedierung auf der Intensivstation: Gefahr einer malignen Hyperthermie",

abstract = "Background: According to the 2010 S3 Guidelines, analgosedation is an option for ventilated patients in intensive care units (ICU). Therefore, adverse effects of volatile anesthetics can occur in areas outside of surgical medical fields. Objective: The aim is to inform ICU physicians about the clinical and legal challenges of a life-threatening pharmacogenetic reaction to inhalational anesthetics, malignant hyperthermia (MH). Discussion: Consequences of an MH crisis for doctors, patients, and relatives regarding patient rights legislation, as well as insurance and employment issues with respect to the German Genetic Diagnostics Act are discussed.",

keywords = "Dantrolene, General anesthesia, German Genetic Diagnostics Act, Malignant hyperthermia, Pharmacogenetics",

author = "W. Klingler and E. Pfenninger",

note = "Publisher Copyright: {\textcopyright} 2018, Springer Medizin Verlag GmbH, ein Teil von Springer Nature.",

year = "2020",

month = mar,

day = "1",

doi = "10.1007/s00063-018-0453-7",

language = "Deutsch",

volume = "115",

pages = "101--106",

journal = "Medizinische Klinik - Intensivmedizin und Notfallmedizin",

issn = "2193-6218",

publisher = "Springer Medizin",

number = "2",

}

TY - JOUR

T1 - Inhalative Analgosedierung auf der Intensivstation

T2 - Gefahr einer malignen Hyperthermie

AU - Klingler, W.

AU - Pfenninger, E.

PY - 2020/3/1

Y1 - 2020/3/1

N2 - Background: According to the 2010 S3 Guidelines, analgosedation is an option for ventilated patients in intensive care units (ICU). Therefore, adverse effects of volatile anesthetics can occur in areas outside of surgical medical fields. Objective: The aim is to inform ICU physicians about the clinical and legal challenges of a life-threatening pharmacogenetic reaction to inhalational anesthetics, malignant hyperthermia (MH). Discussion: Consequences of an MH crisis for doctors, patients, and relatives regarding patient rights legislation, as well as insurance and employment issues with respect to the German Genetic Diagnostics Act are discussed.

AB - Background: According to the 2010 S3 Guidelines, analgosedation is an option for ventilated patients in intensive care units (ICU). Therefore, adverse effects of volatile anesthetics can occur in areas outside of surgical medical fields. Objective: The aim is to inform ICU physicians about the clinical and legal challenges of a life-threatening pharmacogenetic reaction to inhalational anesthetics, malignant hyperthermia (MH). Discussion: Consequences of an MH crisis for doctors, patients, and relatives regarding patient rights legislation, as well as insurance and employment issues with respect to the German Genetic Diagnostics Act are discussed.

KW - Dantrolene

KW - General anesthesia

KW - German Genetic Diagnostics Act

KW - Malignant hyperthermia

KW - Pharmacogenetics

UR - https://www.scopus.com/pages/publications/85052513002

U2 - 10.1007/s00063-018-0453-7

DO - 10.1007/s00063-018-0453-7

M3 - Artikel

C2 - 30076433

AN - SCOPUS:85052513002

SN - 2193-6218

VL - 115

SP - 101

EP - 106

JO - Medizinische Klinik - Intensivmedizin und Notfallmedizin

JF - Medizinische Klinik - Intensivmedizin und Notfallmedizin

IS - 2

ER -

Inhalative Analgosedierung auf der Intensivstation: Gefahr einer malignen Hyperthermie

Abstract

Access to Document

Other files and links

Fingerprint

Cite this